Phase II study assessing the effect of carfilzomib treatment on early free light chain kinetics in myeloma patients with renal impairment

Trial Profile

Phase II study assessing the effect of carfilzomib treatment on early free light chain kinetics in myeloma patients with renal impairment

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 May 2017

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone
  • Indications Multiple myeloma; Renal impairment
  • Focus Therapeutic Use
  • Acronyms ALLG MM16
  • Most Recent Events

    • 19 May 2017 Status changed from not yet recruiting to recruiting.
    • 28 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top